Be-Line Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 08-12-2024
- Paid Up Capital ₹ 0.45 M
as on 08-12-2024
- Company Age 30 Year, 11 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.80 M
as on 08-12-2024
- Revenue 32.85%
(FY 2022)
- Profit -12.57%
(FY 2022)
- Ebitda -58.83%
(FY 2022)
- Net Worth 15.44%
(FY 2022)
- Total Assets 22.09%
(FY 2022)
About Be-Line Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.45 M.
The company currently has active open charges totaling ₹6.80 M.
Karunai Valliammai, Mohamed Banufarook, Sudharaman Sunilkumar, and Five other members serve as directors at the Company.
- CIN/LLPIN
U24231TN1994PTC029511
- Company No.
029511
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Dec 1994
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Thanjavur, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Be-Line Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karunai Valliammai  | Managing Director | 13-Dec-1994 | Current |
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mohamed Banufarook | Director | 14-Aug-1995 | Current |
| Sudharaman Sunilkumar | Director | 05-Apr-2012 | Current |
| Karunai Kadal | Director | 05-Apr-2012 | Current |
| Mohamed Farook | Director | 05-Apr-2012 | Current |
| Janardhanan | Director | 05-Apr-2012 | Current |
| Janardanan Sujatha | Director | 14-Aug-1995 | Current |
Financial Performance of Be-Line Pharmaceuticals.
Be-Line Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 32.85% increase. The company also saw a substantial fall in profitability, with a 12.57% decrease in profit. The company's net worth Soared by an impressive increase of 15.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Be-Line Pharmaceuticals?
In 2022, Be-Line Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Vijaya Bank Creation Date: 22 Oct 2021 | ₹4.60 M | Open |
Vijaya Bank Creation Date: 09 Mar 1998 | ₹2.20 M | Open |
How Many Employees Work at Be-Line Pharmaceuticals?
Unlock and access historical data on people associated with Be-Line Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Be-Line Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Be-Line Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
